Rising poison control calls for kratom signal potential safety concerns with an unregulated botanical that many patients use for pain and opioid withdrawal. Clinicians need to understand kratom’s risk profile to properly counsel patients who may be using it alongside or instead of prescribed therapies.
Poison control centers are reporting increased calls related to kratom, a Southeast Asian plant (Mitragyna speciosa) whose active compounds mitragynine and 7-hydroxymitragynine act on opioid receptors. While some patients use kratom for chronic pain or opioid cessation, the unregulated nature means variable potency and contamination risks. Reported adverse effects include nausea, seizures, respiratory depression, and potential for dependence, particularly with high-dose or frequent use.
“This surge tells us what we already suspected – people are self-medicating with kratom because conventional pain care is failing them, but they’re doing so without clinical oversight or quality assurance. We need better pain treatment options, not just warnings about what patients are already turning to out of desperation.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
FAQ
What is the clinical relevance rating of this cannabis news?
This article has been assigned CED Clinical Relevance #70, which indicates “Notable Clinical Interest.” This rating suggests the findings or developments are emerging and worth monitoring closely by healthcare professionals.
What medical areas does this cannabis research relate to?
The research focuses on pain management, opioid interactions, botanical medicine, and patient safety. These interconnected areas are crucial for understanding cannabis’s role in clinical practice.
How does this relate to opioid use?
The article addresses the relationship between cannabis and opioids in pain management contexts. This is particularly relevant given ongoing concerns about opioid prescribing and potential alternatives or adjunct therapies.
What makes this cannabis news clinically significant?
The classification as “Notable Clinical Interest” indicates this represents emerging findings or policy developments. Healthcare providers should monitor these developments as they may impact clinical decision-making and patient care protocols.
Why is patient safety highlighted in this cannabis research?
Patient safety is a key consideration when evaluating cannabis as a therapeutic option, particularly in pain management. Understanding safety profiles and potential interactions with other medications like opioids is essential for responsible clinical use.